[go: up one dir, main page]

SI3487505T1 - Dajanje in odmerek diaminofenotiazinov - Google Patents

Dajanje in odmerek diaminofenotiazinov

Info

Publication number
SI3487505T1
SI3487505T1 SI201731376T SI201731376T SI3487505T1 SI 3487505 T1 SI3487505 T1 SI 3487505T1 SI 201731376 T SI201731376 T SI 201731376T SI 201731376 T SI201731376 T SI 201731376T SI 3487505 T1 SI3487505 T1 SI 3487505T1
Authority
SI
Slovenia
Prior art keywords
diaminophenothiazines
dosage
administration
Prior art date
Application number
SI201731376T
Other languages
English (en)
Inventor
Claude Michel Wischik
Bjorn Olaf Schelter
Damon Jude Wischik
John Mervyn David Storey
Original Assignee
Wista Laboratories Ltd.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59399428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3487505(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1612863.9A external-priority patent/GB201612863D0/en
Priority claimed from GBGB1710382.1A external-priority patent/GB201710382D0/en
Application filed by Wista Laboratories Ltd., filed Critical Wista Laboratories Ltd.,
Publication of SI3487505T1 publication Critical patent/SI3487505T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/20Agglomerating; Granulating; Tabletting
    • A23P10/28Tabletting; Making food bars by compression of a dry powdered mixture
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/30Encapsulation of particles, e.g. foodstuff additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2203/00Decoration means, markings, information elements, contents indicators
    • B65D2203/02Labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Composite Materials (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
SI201731376T 2016-07-25 2017-07-25 Dajanje in odmerek diaminofenotiazinov SI3487505T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1612863.9A GB201612863D0 (en) 2016-07-25 2016-07-25 Administration and dosage of diaminophenothiazines
GBGB1710382.1A GB201710382D0 (en) 2017-06-29 2017-06-29 Administration and dosage of Diaminophenothiazines
PCT/EP2017/068749 WO2018019823A1 (en) 2016-07-25 2017-07-25 Administration and dosage of diaminophenothiazines
EP17743330.7A EP3487505B1 (en) 2016-07-25 2017-07-25 Administration and dosage of diaminophenothiazines

Publications (1)

Publication Number Publication Date
SI3487505T1 true SI3487505T1 (sl) 2023-10-30

Family

ID=59399428

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731376T SI3487505T1 (sl) 2016-07-25 2017-07-25 Dajanje in odmerek diaminofenotiazinov

Country Status (18)

Country Link
US (4) US11065256B2 (sl)
EP (3) EP3487505B1 (sl)
JP (1) JP7073330B2 (sl)
KR (4) KR102475825B1 (sl)
CN (2) CN116531386A (sl)
AU (3) AU2017301966B2 (sl)
CA (1) CA3031578A1 (sl)
DK (1) DK3487505T3 (sl)
ES (1) ES2946165T3 (sl)
FI (1) FI3487505T3 (sl)
HR (1) HRP20230628T1 (sl)
MX (2) MX385594B (sl)
MY (1) MY201804A (sl)
PL (1) PL3487505T3 (sl)
PT (1) PT3487505T (sl)
SG (1) SG11201900228YA (sl)
SI (1) SI3487505T1 (sl)
WO (1) WO2018019823A1 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2457905T (lt) 2006-07-11 2016-11-10 Wista Laboratories Ltd. Diaminofenotiazino junginių sintezės ir (arba) gryninimo metodai
KR102475825B1 (ko) * 2016-07-25 2022-12-08 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
WO2020020751A1 (en) * 2018-07-26 2020-01-30 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations
CN120148902A (zh) 2018-09-05 2025-06-13 云顶道卫思诊断中心有限公司 神经系统变性疾病的网络方法
EP3952745A1 (en) * 2019-04-10 2022-02-16 Genting Taurx Diagnostic Centre SDN BHD Adaptive neurological testing method
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) * 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
WO2021224146A1 (en) * 2020-05-05 2021-11-11 Wista Laboratories Ltd. Methylthioninium compounds for use in the treatment of hypoxemia
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
JP2025518248A (ja) 2022-05-31 2025-06-12 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム(mt)含有化合物を利用した神経変性障害の処置
WO2024061971A1 (en) 2022-09-21 2024-03-28 Wista Laboratories Ltd. Novel formulations and vehicles
WO2024184146A1 (en) 2023-03-03 2024-09-12 Wista Laboratories Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
BR0311375A (pt) 2002-05-31 2005-03-15 Lundbeck & Co As H Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero
PT1799662E (pt) 2004-09-23 2013-07-09 Wista Lab Ltd Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)
PL2853293T3 (pl) 2006-03-29 2018-05-30 Wista Laboratories Ltd. Związki tioniny i ich zastosowanie
WO2007110629A1 (en) * 2006-03-29 2007-10-04 Wista Laboratories Ltd Inhibitors of protein aggregation
PL2013191T6 (pl) * 2006-03-29 2019-07-31 Wista Laboratories Ltd. Sole 3,7-diamino-10H-fenotiazynowe i ich zastosowanie
LT2457905T (lt) 2006-07-11 2016-11-10 Wista Laboratories Ltd. Diaminofenotiazino junginių sintezės ir (arba) gryninimo metodai
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
CN101820884B (zh) * 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
DK2954932T3 (en) 2007-10-03 2018-12-17 Wista Lab Ltd THERAPEUTIC USE OF DIAMINOPHENOTHIAZINES
EP2227766A2 (en) 2007-11-05 2010-09-15 Wista Laboratories Ltd. Systems for clinical trials
WO2010078659A1 (en) 2009-01-12 2010-07-15 Foster Health Inc. Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions
WO2010104375A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
JP5918136B2 (ja) 2009-09-24 2016-05-18 ウィスタ ラボラトリーズ リミテッド プロセス
SI2480541T1 (sl) 2009-09-24 2016-02-29 Wista Laboratories Ltd. Kristalinični hidrati metiltioninijevega klorida (metilen modrega)
DE102010062810B4 (de) 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
SG10201602111VA (en) 2010-11-30 2016-04-28 Wista Lab Ltd Formulations Comprising Methylthioninium Chloride
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
KR102475825B1 (ko) 2016-07-25 2022-12-08 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
WO2020020751A1 (en) 2018-07-26 2020-01-30 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions

Also Published As

Publication number Publication date
CN109789148A (zh) 2019-05-21
KR102475825B1 (ko) 2022-12-08
EP4335517A3 (en) 2024-08-07
US12310973B2 (en) 2025-05-27
JP7073330B2 (ja) 2022-05-23
EP3487505A1 (en) 2019-05-29
MX385594B (es) 2025-03-18
AU2022291420B2 (en) 2024-05-09
EP4223297A3 (en) 2023-11-15
US20230346794A1 (en) 2023-11-02
PL3487505T3 (pl) 2023-10-09
US11759469B2 (en) 2023-09-19
MX2021009899A (es) 2021-09-14
US20220008431A1 (en) 2022-01-13
FI3487505T3 (fi) 2023-06-05
WO2018019823A1 (en) 2018-02-01
WO2018019823A8 (en) 2018-04-05
US20200016165A1 (en) 2020-01-16
CN116531386A (zh) 2023-08-04
EP4223297A2 (en) 2023-08-09
MX2019000946A (es) 2019-05-13
US12128051B2 (en) 2024-10-29
ES2946165T3 (es) 2023-07-13
AU2022291420A1 (en) 2023-02-02
MY201804A (en) 2024-03-19
EP3487505B1 (en) 2023-05-03
AU2023203084A1 (en) 2023-06-08
KR102592614B1 (ko) 2023-10-24
EP4335517A2 (en) 2024-03-13
KR20230058533A (ko) 2023-05-03
PT3487505T (pt) 2023-06-07
US20230165877A1 (en) 2023-06-01
US11065256B2 (en) 2021-07-20
AU2017301966A1 (en) 2019-03-07
KR20190031552A (ko) 2019-03-26
JP2019527216A (ja) 2019-09-26
AU2023203084B2 (en) 2025-03-06
CA3031578A1 (en) 2018-02-01
KR20240074909A (ko) 2024-05-28
AU2017301966B2 (en) 2022-09-22
SG11201900228YA (en) 2019-02-27
HRP20230628T1 (hr) 2023-09-29
KR20230003261A (ko) 2023-01-05
DK3487505T3 (da) 2023-05-30

Similar Documents

Publication Publication Date Title
ZA202102219B (en) Dosage and administration of non-fucosylated anti-cd40 antibodies
PT3487505T (pt) Administração e dosagem de diaminofenotiazinas
IL287749A (en) Compositions for administering implantable drugs and methods of their use
IL251834B1 (en) Pharmaceutical compositions containing peptide variants and methods of using them
IL254552A0 (en) Polycyclic carbamoylpyridone compounds and their pharmaceutical uses
GB201620066D0 (en) Solid Pharmaceutical dosage formulations and processes
GB201817116D0 (en) Pharmaceutical preparation of palbociclic and preparation method thereof
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
RS65120B1 (sr) Farmaceutske formulacije i postupci za njihovu upotrebu
IL258192A (en) Medicinal compounds and methods of using them
ZA201805977B (en) Mycobacteriophages capable of delivering auto-luminescent elements and uses thereof
IL253791A0 (en) Doses and methods of administration of telavancin
GB201406172D0 (en) Therapy and pharmaceutical composition
PT3503885T (pt) Composição farmacêutica e métodos de utilização
ZA201902085B (en) Medicinal use of serrulatane diterpenes
PL3328385T3 (pl) Postać dawkowania leku alkaloidu barwinka
GB201519644D0 (en) Therapy and pharmaceutical composition
HK40106579A (en) Administration and dosage of diaminophenothiazines
HK40097117A (en) Administration and dosage of diaminophenothiazines
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
GB201710382D0 (en) Administration and dosage of Diaminophenothiazines
IL252080A0 (en) Oral administration of drugs that are unstable or poorly absorbed
GB201718320D0 (en) Therapeutic substances and their preparation